FDA clears Iroko pain drug Tivorbex for US market
This article was originally published in Scrip
Executive Summary
The FDA has approved Iroko Pharmaceuticals nonsteroidal anti-inflammatory drug (NSAID) Tivorbex (indomethacin) 20mg and 40mg capsules to treat mild to moderate acute pain in adults.